[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Data from P2 DESTINY-Breast01 trial (NCT03248492) for (HER2)-positive breast cancer in H2 2019 (AstraZeneca) - Apr 26, 2019 - Q1 2019 Results: Data from P3 DESTINY-Breast02 trial (NCT03523585) for pre-treated HER2 breast cancer in 2020 or later 
P2 data • P3 data
https://www.astrazeneca.com/investor-relations/results-and-presentations.html
 
Apr 26, 2019
 
 
d8c4583d-4a9d-4910-8d0b-8505f7c23f0b.jpg